MetasTx Strengthens Senior Team with Industry Veteran Jennifer Quigley
PITTSBURGH, PA (September 17, 2024)— MetasTx LLC, a biopharmaceutical company dedicated to developing innovative therapies for cancer metastasis, is pleased to announce the appointment of Jennifer Quigley to its Advisory Board. With over a decade of experience driving innovation at the intersection of diagnostics, data, and therapeutics, Quigley’s expertise will be instrumental in advancing MetasTx's mission of improving patient care through precision medicine.
Quigley’s career has been defined by her leadership roles in some of the world’s foremost healthcare organizations, including Novartis, LabCorp, PathAI, and Miraca Life Sciences. Her experience includes the successful launch of numerous commercial tests and programs, as well as the development of strategic partnerships that have accelerated the adoption of innovative medical solutions.
“Jennifer’s track record in commercialization strategy and her deep understanding of diagnostics make her a perfect fit for our advisory board,” said Harvey Homan, CEO of MetasTx. “Her insights will be invaluable as we continue to expand our pipeline and scale our business. We are thrilled to welcome her to our team, where she will undoubtedly help us achieve our mission of transforming cancer treatment.”
Quigley’s expertise in commercial strategy, particularly in the fields of precision medicine and diagnostics, will be crucial as MetasTx navigates the complex landscape of healthcare commercialization. Her contributions are expected to enhance the company's ability to bring innovative science to market.
“I am excited to join MetasTx at such a pivotal time in their growth,” Quigley said. “I look forward to contributing to their efforts to bring transformative healthcare solutions to market and improve patient outcomes worldwide.”
About MetasTx
MetasTx LLC is a biopharmaceutical company committed to developing groundbreaking therapies for the treatment and prevention of cancer metastasis. Building on decades of research into p21-activated kinase (PAK-1)—a key driver of metastasis in solid tumors, including prostate, breast, and skin cancers—MetasTx aims to revolutionize cancer treatment and improve patient outcomes. For more information, visit www.MetasTx.com.
About AMS Communications
AMS Communications is a boutique Public Relations and Digital Media Agency in the Greater Philadelphia area. We are committed to elevating our client's awareness and engagement by telling their stories through earned and paid media. If you'd like to follow our success in real-time, follow us on social media.
Contacts
